Literature DB >> 28801217

Evaluation of Unplanned Hospital Readmissions After Major Urologic Inpatient Surgery in the Era of Accountable Care.

Benjamin V Stone1, Matthew R Cohn1, Nicholas M Donin2, Michael Schulster1, James S Wysock3, Danil V Makarov4, Marc A Bjurlin5.   

Abstract

OBJECTIVE: To provide a multi-institutional analysis of clinical factors predicting unplanned hospital readmission after major inpatient urologic surgery.
MATERIALS AND METHODS: The American College of Surgeons National Surgical Quality Improvement Program is a risk-adjusted data collection mechanism for analyzing clinical outcomes data including 30-day perioperative readmissions and complications. We identified 23,108 patients who underwent major inpatient urologic surgery from 2011 to 2012. Readmission rates were determined and stratified by procedure type. Multiple logistic regression was used to determine independent risk factors for 30-day unplanned hospital readmissions.
RESULTS: Of a total of 23,108 patients undergoing urologic surgery, 1329 patients (5.8%) had unplanned readmissions. Upper tract reconstruction and urinary diversion without cystectomy (21/102) and with cystectomy (291/1662) had the highest rates of readmission of all procedures analyzed. Readmitted patients had a 64.2% (853/1329) and 64.4% (855/1329) rate of major and minor complications, respectively, compared with 6.7% (1459/21,779) and 15.9% (3462/21,779) for patients not readmitted (P <.02). Organ space infection (odds ratio [OR] 15.23), pulmonary embolism (OR 12.14), deep venous thrombosis (OR 10.96), and return to the operating room (OR 8.46) were the most substantial predictors of readmission. Laparoscopic-robotic procedures had significantly lower readmission rates compared with open procedures for prostatectomy, partial nephrectomy, and nephrectomy (P <.01).
CONCLUSION: Readmission after inpatient urologic surgery occurs at a rate of 5.8%, with cystectomy and urinary diversion demonstrating the highest rates. Major and minor postoperative complications were the most substantial predictors of readmission. These results may guide risk reduction initiatives to prevent readmissions after major urologic surgery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28801217     DOI: 10.1016/j.urology.2017.07.043

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Reversal of rocuronium-induced neuromuscular block: is it time for sugammadex to replace neostigmine?

Authors:  M Carron; A De Cassai; G Ieppariello
Journal:  Br J Anaesth       Date:  2019-05-16       Impact factor: 9.166

2.  Postpartum length of stay and risk for readmission among women with preeclampsia.

Authors:  Timothy Wen; Victoria X Yu; Jason D Wright; Dena Goffman; Frank Attenello; William J Mack; Mary D'Alton; Alexander M Friedman
Journal:  J Matern Fetal Neonatal Med       Date:  2018-09-10

3.  Enterocystoplasty and appendicovesicostomy in adults: a description of demographics and 30-day outcomes of bladder augmentation.

Authors:  Joseph G Brungardt; Caleb S Miller; Kurt P Schropp
Journal:  Am J Clin Exp Urol       Date:  2020-08-15

4.  Comparison of overall survival and unplanned hospital readmissions between partial and radical nephrectomy for cT1a and cT1b renal masses.

Authors:  Julio T Chong; David Paulucci; Marc Lubin; Alp Tuna Beksac; Greg Gin; John P Sfakianos; Ketan K Badani
Journal:  Ther Adv Urol       Date:  2018-11-09

5.  Unplanned 30-day readmission rates in patients undergoing endo-urological surgeries for upper urinary tract calculi.

Authors:  Manoj Kumar; Siddharth Pandey; Ajay Aggarwal; Deepanshu Sharma; Gaurav Garg; Samarth Agarwal; Ashish Sharma; Satyanarayan Sankhwar
Journal:  Investig Clin Urol       Date:  2018-08-31

6.  Frailty predicts outcome of partial nephrectomy and guides treatment decision towards active surveillance and tumor ablation.

Authors:  M T Walach; M F Wunderle; N Haertel; J K Mühlbauer; K F Kowalewski; N Wagener; N Rathmann; M C Kriegmair
Journal:  World J Urol       Date:  2021-01-30       Impact factor: 4.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.